Treatment Changes, Healthcare Resource Utilization, and Costs Among Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy: A Claims Database Study

Authors

Anjali T. Owens, Center for Inherited Cardiovascular Disease, Perelman Center for Advanced Medicine, University of Pennsylvania Perelman School of Medicine, 11th Floor South Tower, 3400 Civic Center Blvd, Philadelphia, PA, 19014, USA. anjali.owens@pennmedicine.upenn.edu.
Megan B. Sutton, Myokardia, Inc., a wholly owned subsidiary of Bristol Myers Squibb, Brisbane, CA, USA.
Wei Gao, Analysis Group, Inc., Boston, MA, USA.
Jennifer T. Fine, Myokardia, Inc., a wholly owned subsidiary of Bristol Myers Squibb, Brisbane, CA, USA.
Jipan Xie, Analysis Group, Inc., Los Angeles, CA, USA.
Srihari S. Naidu, Department of Cardiology, Westchester Medical Center, Westchester Medical Center Health Network, New York Medical College, Valhalla, NY, USA.
Nihar R. Desai, Section of Cardiovascular Medicine, Department of Medicine, Yale University School of Medicine, New Haven, CT, USA.

Author Type(s)

Faculty

Journal Title

Cardiology and Therapy

First Page

249

Last Page

267

Document Type

Article

Publication Date

6-1-2022

Department

Medicine

Abstract

INTRODUCTION: There is limited evidence on therapies for obstructive hypertrophic cardiomyopathy (HCM), and data regarding treatment patterns and cost are scarce. This study assessed treatment patterns and economic outcomes in patients with symptomatic obstructive HCM. METHODS: Adults with symptomatic obstructive HCM as per study design and treated with pharmacotherapies [beta blockers (BBs), calcium channel blockers (CCBs), BB + CCB, or disopyramide] or procedures (septal reduction therapy, heart transplantation, implantable cardioverter-defibrillator, and pacemaker implantation) were identified from the IBM® MarketScan® Commercial and Medicare Supplemental database (January 2009-March 2019). Patients had 12-month continuous eligibility before and after (study period) treatment initiation (index treatment). Healthcare resource utilization (HRU), costs, and treatment changes were assessed. RESULTS: Of the 4883 patients included in the analysis, 85% received pharmacotherapies (BB 52.5%; CCB 11.7%; BB + CCB 17.7%; disopyramide 2.4%) and 15.7% underwent procedures. During the study period, 38, 34, and 100% of all patients had ≥ 1 inpatient stay, emergency room (ER) visit, and outpatient visit, respectively; mean total healthcare costs were US$53,053. Patients undergoing procedures had the highest HRU and costs across groups. Among patients receiving pharmacotherapies, HRU was lowest with BBs and highest with disopyramide. Treatment changes were observed in 43.8% of patients receiving pharmacotherapies. CONCLUSIONS: Patients experienced high rates of treatment changes, and the economic burden associated with symptomatic obstructive HCM increased as therapy escalated. More effective therapies are needed to stabilize or decrease the economic burden of obstructive HCM.

Recommended Citation

Owens, A. T., Sutton, M. B., Gao, W., Fine, J. T., Xie, J., Naidu, S. S., & Desai, N. R. (2022). Treatment Changes, Healthcare Resource Utilization, and Costs Among Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy: A Claims Database Study. Cardiology and Therapy, 11 (2), 249-267. https://doi.org/10.1007/s40119-022-00257-7